An April 2022 study by Rutgers said,
“This work shows the kisspeptin receptor signaling pathway has a potential therapeutic role in Non-Alcoholic Fatty Liver Disease.”
“It does this by protecting against the development of fat in the liver and reducing inflammation and fibrosis. As such, it has the potential to favorably impact the health and lives of millions of patients around the globe.”